Paper2545337
Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up.
de Vries EG and 6 others. Cancer Res, 1989. Cited by 77 papers, by iCite.
Cite this record
ConductScience Library. Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Papers, record 2545337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2545337
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma, Small Cell | Major topic |
| Lung Neoplasms | Major topic |
| Cell Survival | |
| DNA Damage | |
| Doxorubicin | |
| Drug Resistance | |
| Follow-Up Studies | |
| Humans | |
| Sulfhydryl Compounds | |
| Tumor Cells, Cultured |
Source PubMed
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 31446534 | Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines. | Invest New Drugs | 2020 | https://conductscience.org/library/papers/31446534 | PubMed |
| 30669448 | Expression of Proteolytic Enzymes by Small Cell Lung Cancer Circulating Tumor Cell Lines. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/30669448 | PubMed |
| 28315949 | 89Zr-Onartuzumab PET imaging of c-MET receptor dynamics. | Eur J Nucl Med Mol Imaging | 2017 | https://conductscience.org/library/papers/28315949 | PubMed |
| 23322202 | Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus. | Br J Cancer | 2013 | https://conductscience.org/library/papers/23322202 | PubMed |
| 22952424 | CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. | Neoplasia | 2012 | https://conductscience.org/library/papers/22952424 | PubMed |
| 12771999 | Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11)-induced growth inhibition. | Br J Cancer | 2003 | https://conductscience.org/library/papers/12771999 | PubMed |
| 9569045 | Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9569045 | PubMed |
| 9472628 | 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9472628 | PubMed |
| 8913832 | Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. | Invest New Drugs | 1996 | https://conductscience.org/library/papers/8913832 | PubMed |
| 8519652 | Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. | Br J Cancer | 1995 | https://conductscience.org/library/papers/8519652 | PubMed |
| 8485812 | Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8485812 | PubMed |
| 8094293 | Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8094293 | PubMed |
| 8013423 | DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. | Environ Health Perspect | 1993 | https://conductscience.org/library/papers/8013423 | PubMed |
| 7832767 | Suppression of sterol 27-hydroxylase mRNA and transcriptional activity by bile acids in cultured rat hepatocytes. | Biochem J | 1995 | https://conductscience.org/library/papers/7832767 | PubMed |
| 7765327 | Human cell lines as models for multidrug resistance in solid tumours. | Cytotechnology | 1993 | https://conductscience.org/library/papers/7765327 | PubMed |
| 7765324 | Glutathione-related enzymes, glutathione and multidrug resistance. | Cytotechnology | 1993 | https://conductscience.org/library/papers/7765324 | PubMed |
| 7764460 | Antibodies in the study of multiple drug resistance. | Cytotechnology | 1993 | https://conductscience.org/library/papers/7764460 | PubMed |
| 1657425 | Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/1657425 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CAT | 847 | PubTator's text mining | https://conductscience.org/library/genes/847 | NCBI Gene |
| GSTK1 | 373156 | PubTator's text mining | https://conductscience.org/library/genes/373156 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2545337
GET https://conductscience.org/api/papers/v1/2545337/authors